Skip to main content

remdesivir Archives

Resistance to COVID-19 drug detected in lab study

May. 10, 2022—Vanderbilt research shows that the virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism.  

Read more


COVID treatment studied by VUMC gains FDA approval

Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Read more


THA honors VUMC efforts in remdesivir distribution

Oct. 14, 2020—A team of pharmacists and physicians from Vanderbilt University Medical Center that this spring took on statewide distribution of remdesivir, an urgently needed investigational drug for severely ill patients hospitalized with COVID-19, has received the President’s Award from the Tennessee Hospital Association (THA).

Read more


New data offer insights on COVID treatments for people with cancer

Jul. 22, 2020—Newly released data on treatment outcomes of people with cancer diagnosed with COVID-19 reveal a racial disparity in access to Remdesivir, an antiviral drug that has been shown to shorten hospital stays, and increased mortality associated with dexamethasone, a steroid that has had the opposite effect in the general patient population.

Read more


New study supports remdesivir as COVID-19 treatment

Jul. 9, 2020—This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

Read more


Remdesivir helps reduce COVID-19 recovery time: study

Jun. 4, 2020—The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

Read more


Vanderbilt investigators encouraged by early results of placebo-controlled remdesivir trial

Apr. 29, 2020—A preliminary look at data from hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) in a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir is showing promising results.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more